Loss of HER2 Positivity After Anti-Her2 Chemotherapy in HER2-positive Gastric Cancer Patients: Results of the GASTric Cancer HER2 Reassessment Study 3 (GASTHER3)

Gastric Cancer - Germany
doi 10.1007/s10120-018-0891-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

HER2 Loss in HER2-positive Gastric or Gastroesophageal Cancer After Trastuzumab Therapy: Implication for Further Clinical Research

International Journal of Cancer
Cancer ResearchOncology
2016English

Prognostic Implications of HER2 Heterogeneity in Gastric Cancer

Oncotarget
Oncology
2018English

HER2 Testing in Gastric Cancer: A Practical Approach

Modern Pathology
Forensic MedicinePathology
2012English

Droplet Digital PCR Measurement of HER2 in Patients With Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2015English

Perspectives of HER2-targeting in Gastric and Esophageal Cancer

Expert Opinion on Investigational Drugs
MedicinePharmacology
2017English

Clinical Significance of Intratumoral HER2 Heterogeneity on Trastuzumab Efficacy Using Endoscopic Biopsy Specimens in Patients With Advanced HER2 Positive Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2018English

Brain Metastases in Asian HER2-positive Breast Cancer Patients: Anti-Her2 Treatments and Their Impact on Survival

British Journal of Cancer
Cancer ResearchOncology
2012English

Benefit of Post Mastectomy Radiation Therapy (PMRT) in Node-Positive, HER2-Positive Patients With Breast Cancer Receiving Anti-Her2 Treatments

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2020English

Positive Prognostic Value of HER2-HER3 Co-Expression and P-mTOR in Gastric Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy